表皮生长因子酪氨酸激酶抑制剂用于治疗非小细胞肺癌软脑膜转移患者
该研究回顾性分析2003年1月1日至2013年10月31日在本院治疗的25例非小细胞肺癌软脑膜转移患者,评估临床特征、治疗及预后因素。全组中位总生存期为4.9个月,接受EGFR-TKIs治疗者中位生存期长于未接受者(5.3个月 vs 1.2个月,P=0.022)。多因素分析显示女性(P=0.012)和EGFR-TKIs治疗(P=0.008)为良好预后的显著预测因素。
要点
- 全组25例NSCLC软脑膜转移患者中位总生存期为4.9个月。
- 接受EGFR-TKIs治疗者中位生存期5.3个月,未接受者为1.2个月(P=0.022)。
- 多因素分析显示女性和EGFR-TKIs治疗是良好预后的显著预测因素。
核心结论
- EGFR-TKIs治疗可能使NSCLC软脑膜转移患者获益。
- 女性患者和EGFR-TKIs治疗是生存的良好预后因素。
研究设计与样本
- 回顾性分析2003年1月1日至2013年10月31日在本院治疗的25例NSCLC软脑膜转移患者的病历资料,分析临床特征、治疗及生存和预后因素。
主要发现
- NSCLC软脑膜转移更多见于女性患者(64.0%),多数为腺癌(72.0%)。
- 20例(80.0%)患者接受抗癌治疗,其中17例接受EGFR-TKIs治疗。
- 全组(25例)诊断软脑膜转移后中位总生存期为4.9个月。
- 接受EGFR-TKIs治疗者中位生存期长于未接受者(5.3个月 vs 1.2个月,P=0.022)。
- 11例在靶向治疗前发生软脑膜转移的患者接受EGFR-TKIs治疗后中位生存期延长至8.1个月。
关键数值与推荐
- 单因素分析显示女性和EGFR-TKIs治疗是影响生存的有利预后因素(P<0.05);年龄、初诊时即存在软脑膜转移、EGFR-TKIs治疗期间发生软脑膜转移、全脑放疗、鞘内化疗或全身细胞毒化疗与中位总生存期无关(P>0.05)。
- 多因素分析显示女性(P=0.012)和EGFR-TKIs治疗(P=0.008)是良好预后的显著预测因素。
临床怎么用
- 原文结论认为EGFR-TKIs治疗可能使NSCLC软脑膜转移患者获益,女性和EGFR-TKIs治疗是生存的良好预后因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: The aim of this study was to identify the clinical features and prognostic factors of leptomeningeal metastasis (LM) in non-small cell lung cancer (NSCLC) patients undergoing treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Methods: Twenty-five cases of NSCLC with LM, treated in our hospital during January 1, 2003 to October 31, 2013, were enrolled in this study. Medical records were reviewed for clinical features and treatments, and the survival and prognostic factors were analyzed. Results: NSCLC-LM were more common in female patients (64.0%), and most were adenocarcinomas (72.0%). Twenty (80.0%) patients underwent anti-cancer treatment, among them 17 patients underwent EGFR-TKIs treatment.The median overall survival (mOS) after the diagnosis of LM was 4.9 months for the whole group (25 cases). Patients receiving EGFR-TKIs treatment had a longer median survival than patients not receiving EGFR-TKIs (5.3 months vs. 1.2 months, P=0.022). Eleven patients who developed LM before the targeted therapy had a prolonged median survival of 8.1 months after EGFR-TKIs treatment. The univariate analysis showed that female gender and EGFR-TKIs treatment were favorable prognostic factors influencing the survival (P<0.05), while age, LM at the time of initial diagnosis, LM developed during the EGFR-TKIs treatment, whole-brain radiotherapy (WBRT), intrathecal chemotherapy, or systemic cytotoxic chemotherapy were not associated with mOS (P>0.05 for all). The multivariate analysis showed that female gender (P=0.012) and EGFR-TKIs treatment (P=0.008) were significant predictors of a good prognosis. Conclusions: EGFR-TKIs treatment may confer benefit for NSCLC-LM patients. Female patients and EGFR-TKIs treatment are favorable prognostic factors for survival.
引用
- Xu Y, Zhong W, Zhao J, et al. [Epidermal growth factor tyrosine kinase inhibitors used in the treatment of NSCLC patients with leptomeningeal metastasis]. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27998469. doi:10.3760/cma.j.issn.0253-3766.2016.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。